skip to main content
Idioma:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Busca Simples
Refinado por: Base de dados/Biblioteca: BMJ Journals (Open Access) remover Base de dados/Biblioteca: SpringerLink remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
355 First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies
355 First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies
Material Type:
Artigo 		Adicionar ao Meu Espaço

355 First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies

Shah, Nina ; Tan, Alan ; Budde, Lihua ; Hofmeister, Craig ; Cowan, Andrew ; Saeed, Hayder ; Ye, Jing ; Cairo, Mitchell ; Rizzieri, David ; Orloff, Gregory ; Ge, Xue Snow ; Lee, Zachary ; Dixit, Neha ; Nieves, Wildaliz ; Vimal, Mona ; Ma, Haijun ; Miyazaki, Takahiro ; Madakamutil, Loui ; Marcondes, Mario ; Lin, Wei ; Tagliaferri, Mary ; Zalevsky, Jonathan ; Patel, Krina

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A216-A217 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
2
Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
Material Type:
Artigo 		Adicionar ao Meu Espaço

Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

Amin, Asim ; Dudek, Arkadiusz Z ; Logan, Theodore F ; Lance, Raymond S ; Holzbeierlein, Jeffrey M ; Knox, Jennifer J ; Master, Viraj A ; Pal, Sumanta K ; Miller, Jr, Wilson H ; Karsh, Lawrence I ; Tcherepanova, Irina Y ; DeBenedette, Mark A ; Williams, W Lee ; Plessinger, Douglas C ; Nicolette, Charles A ; Figlin, Robert A

Journal for immunotherapy of cancer, 2015-04, Vol.3 (1), p.14-14, Article 14 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível

Citações Citado por
3
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
Material Type:
Artigo 		Adicionar ao Meu Espaço

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors

Taylor, Kirsty ; Loo Yau, Helen ; Chakravarthy, Ankur ; Wang, Ben ; Shen, Shu Yi ; Ettayebi, Ilias ; Ishak, Charles A ; Bedard, Philippe L ; Abdul Razak, Albiruni ; R Hansen, Aaron ; Spreafico, Anna ; Cescon, Dave ; Butler, Marcus O ; Oza, Amit M ; Lheureux, Stephanie ; Stjepanovic, Neda ; Van As, Brendan ; Boross-Harmer, Sarah ; Wang, Lisa ; Pugh, Trevor J ; Ohashi, Pamela S ; Siu, Lillian L ; De Carvalho, Daniel D

Journal for immunotherapy of cancer, 2020-08, Vol.8 (2), p.e000883 [Periódico revisado por pares]

England: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
4
Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial
Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial

Luke, Jason J. ; Zha, Yuanyuan ; Matijevich, Karen ; Gajewski, Thomas F.

Journal for immunotherapy of cancer, 2016-06, Vol.4 (1), p.35-35, Article 35 [Periódico revisado por pares]

England: BMJ Publishing Group Ltd

Texto completo disponível

Citações Citado por
5
Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities
Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities
Material Type:
Artigo 		Adicionar ao Meu Espaço

Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities

Christodoulou, Ilias ; Ho, Won Jin ; Marple, Andrew ; Ravich, Jonas W ; Tam, Ada ; Rahnama, Ruyan ; Fearnow, Adam ; Rietberg, Cambrynne ; Yanik, Sean ; Solomou, Elena E ; Varadhan, Ravi ; Koldobskiy, Michael A ; Bonifant, Challice L

Journal for immunotherapy of cancer, 2021-12, Vol.9 (12), p.e003894 [Periódico revisado por pares]

England: BMJ Publishing Group Ltd

Texto completo disponível

Citações Citado por
6
Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions
Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions
Material Type:
Artigo 		Adicionar ao Meu Espaço

Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions

Bauché, David ; Mauze, Smita ; Kochel, Christina ; Grein, Jeff ; Sawant, Anandi ; Zybina, Yulia ; Blumenschein, Wendy ; Yang, Peng ; Annamalai, Lakshmanan ; Yearley, Jennifer H ; Punnonen, Juha ; Bowman, Edward P ; Chackerian, Alissa ; Laface, Drake

Journal for immunotherapy of cancer, 2020-10, Vol.8 (2), p.e001584 [Periódico revisado por pares]

England: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
7
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Papadatos-Pastos, Dionysis ; Yuan, Wei ; Pal, Abhijit ; Crespo, Mateus ; Ferreira, Ana ; Gurel, Bora ; Prout, Toby ; Ameratunga, Malaka ; Chénard-Poirier, Maxime ; Curcean, Andra ; Bertan, Claudia ; Baker, Chloe ; Miranda, Susana ; Masrour, Nahal ; Chen, Wentin ; Pereira, Rita ; Figueiredo, Ines ; Morilla, Ricardo ; Jenkins, Ben ; Zachariou, Anna ; Riisnaes, Ruth ; Parmar, Mona ; Turner, Alison ; Carreira, Suzanne ; Yap, Christina ; Brown, Robert ; Tunariu, Nina ; Banerji, Udai ; Lopez, Juanita ; de Bono, Johann ; Minchom, Anna

Journal for immunotherapy of cancer, 2022-06, Vol.10 (6), p.e004495 [Periódico revisado por pares]

London: BMJ Publishing Group Ltd

Texto completo disponível

Citações Citado por
8
Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells
Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells
Material Type:
Artigo 		Adicionar ao Meu Espaço

Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells

Pollack, Seth M ; Jones, Robin L ; Farrar, Erik A ; Lai, Ivy P ; Lee, Sylvia M ; Cao, Jianhong ; Pillarisetty, Venu G ; Hoch, Benjamin L ; Gullett, Ashley ; Bleakley, Marie ; Conrad, 3rd, Ernest U ; Eary, Janet F ; Shibuya, Kendall C ; Warren, Edus H ; Carstens, Jason N ; Heimfeld, Shelly ; Riddell, Stanley R ; Yee, Cassian

Journal for immunotherapy of cancer, 2014-10, Vol.2 (1), p.36-36, Article 36 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível

Citações Citado por
9
354 A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer
354 A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

354 A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer

Pai, Sara ; Adkins, Douglas ; Wirth, Lori ; Chung, Christine ; Gibson, Michael ; Ammar Sukari ; Worden, Francis ; Colevas, Dimitrios ; Saba, Nabil ; Burtness, Barbara ; Rodriguez, Cristina ; Bauman, Julie ; Glisson, Bonnie ; Dunn, Lara ; Suri, Anish ; Haydock, Mark ; Quayle, Steven ; Cemerski, Saso ; Leader, Megan ; Brown, Jason ; Pienta, Kenneth ; Simcox, Mary

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A216-A216 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.